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mately 1.6 million new cases and 1.4 million deaths due to
lung cancer [1]. Lung cancer is the number one cause of death
from cancer in males and the number two cause of cancer
death in females globally. Lung cancer fatality ratio (ratio of
mortality to incidence) was estimated to be 0.86 in the
GLOBOSCAN Report. The 5-year survival rate for lung cancer
varies by country but is generally 5–15% [1,2].
The poor 5-year survival rate is largely due to the advanced
stage of the disease at diagnosis. In the USA only 15% of lung
cancers are localized at the time of initial diagnosis and over
50% have stage IV disease [2]. The main reason for diagnosis at
a late stage is that the early stage the disease is asymptomatic
and screening for lung cancer has not been routine or recom-
mended in most countries.
The Prostate, Lung, Colorectal, and Ovarian Cancer Screening
Trial in North America randomized 154,900 participants aged
55–74 years to screening with annual chest radiographs or
usual care for 4 years with 13 years of follow-up. Annual
screening with chest radiograph did not reduce lung cancer
mortality compared to usual care [3]. This trial conﬁrmed the
results of previously conducted randomized controlled trials
evaluating the role of screening with chest roentgenograms
that failed to show any mortality beneﬁt [4,5].
Screening for lung cancer with low-dose (radiation) com-
puted tomography (LDCT) was initiated by Japanese investiga-
tors in the 1990s [6,7]. They demonstrated that screening with
LDCT was feasible and that it detected 2–3 times more lung
cancers than chest radiographs obtained at the same time.
Additionally, many more of the LDCT detected lung cancers
were at an earlier stage. These studies and other conducted in
the U.S. helped set the stage for the deﬁnitive randomized
control trial with LDCT [8,9].
In 2011, the results of the National Lung Screening Trial
(NLST) were reported. The NLST randomized 53,454 persons
at high risk for lung cancer to screening with LDCT or chest
radiograph for 3 years [10]. Participants were followed for a
median duration of 6.5 years. Screening with LDCT resulted in
a 20% relative reduction in mortality from lung cancer as
compared to chest radiographic screening and a 6.7% all
cause mortality reduction.
In 2013, the results of the initial or baseline screening and
the two incidence screenings have been reported [11,12]. More
lung cancers were detected with LDCT after three scans than
with chest radiographs (715 vs. 467). Additionally, more stage I
lung cancers and fewer stage III/IV cancers were detected witheach round of screening. The sensitivity and speciﬁcity of LDCT
screening for detecting lung cancer were approximately 94%
and 73%, respectively for each round. By comparison, the
sensitivity of chest radiographs was 60–70% over the three
rounds of screening [11,12].
It has been estimated that screening with LDCT could
decrease lung cancer deaths by 12,000 persons each year in
the United States if screening was to be implemented in all
eligible participants [13]. However, currently there are 160,000
lung cancer deaths per year in the United States. The eligibility
criteria for screening in the NLST currently apply to only 26.7%
of the lung cancers in the United States [14]. So there is a need
for a better lung cancer risk prediction model to use for deciding
on whom to screen.
There has been great interest in lung cancer risk prediction
models [15–17]. In North America, a risk prediction model was
developed based on data from the PLCO trial. The PLCO risk
model criteria were compared with the NLST eligibility criteria
for accuracy to detect lung cancer. The PLCO risk model was
more sensitive than the NLST criteria for lung cancer detection.
Overall, the model identiﬁed 81 more of the 678 lung cancers
(11.9%) than did the NLST criteria [16,17].
A recent analysis evaluated the beneﬁt of screening in the
NLST according to risk of lung cancer death [18]. Five-year risk of
death from lung cancer was divided into quintiles. The 60% of
participants at highest risk for lung cancer death (quintiles 3–5)
accounted for 88% of the screening prevented deaths. The 20% of
the NLST participants at lowest risk (quintile 1) accounted for
only 1% of prevented lung cancer deaths. Similar trends in lung
cancer mortality ratios were observed whether risk quintiles
were based on predicted risk of lung cancer or on the risk of lung
cancer deaths (P¼0.90) [18].
The PLCO lung cancer risk calculator has been reported
and is available on line at http://www.brocku.ca/lung-cancer-
risk-calculator [17]. It does not apply to non-smokers. It was
developed on data from a North American population [16].
There are differences in lung cancer in Japan as compared to
North America. Most notable is the difference in frequency of
the epidermal growth factor receptor mutations [19]. It is
uncertain if the PLCO (North American) risk model would be
applicable in Japan/Asia. This model should be evaluated in
different populations with varying medical systems. These
population studies should be in well designed prospective
trials [17].
In 2013, both the American Cancer Society and the United
States Preventive Health Services Task Force have endorsed
E d i t o r i a l / r e s p i r a t o r y i n v e s t i g a t i o n 5 1 ( 2 0 1 3 ) 2 0 5 – 2 0 6206screening for lung cancer with LDCT in high-risk individuals
[20,21]. This high-risk group has been deﬁned as those
individuals meeting the NLST screening criteria. Future
research will be directed at better deﬁning those at risk. Risk
assessment will very likely be enhanced by the addition of
biomarkers from blood, sputum, breath, or urine. Intense
research in biomarkers of risk is currently underway [22–24].
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